Aprea Therapeutics Announces Proposed Public Offering of Common Stock
22 févr. 2023 16h05 HE
|
Aprea Therapeutics
DOYLESTOWN, Pa., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a biopharmaceutical company focused on developing novel synthetic...
Aprea Therapeutics Announces Phase II SBIR Award from the National Cancer Institute (NCI)
15 févr. 2023 08h00 HE
|
Aprea Therapeutics
DOYLESTOWN, Pa., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics...
Aprea Therapeutics Announces One-for-Twenty Reverse Stock Split
13 févr. 2023 07h00 HE
|
Aprea Therapeutics
DOYLESTOWN, Pa., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (the “Company”), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer...
Aprea Therapeutics Appoints John Hamill as Chief Financial Officer
30 janv. 2023 08h00 HE
|
Aprea Therapeutics
DOYLESTOWN, Pa., Jan. 30, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics...
Aprea Therapeutics to Participate in 6th Annual DNA Damage and Response (DDR) Inhibitors Summit
19 janv. 2023 08h00 HE
|
Aprea Therapeutics
DOYLESTOWN, Pa., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics...
Aprea Therapeutics Announces Dosing of First Patient in Phase 1/2a Clinical Trial of Oral ATR Inhibitor ATRN-119 for the Treatment of Advanced Solid Tumors
11 janv. 2023 08h00 HE
|
Aprea Therapeutics
DOYLESTOWN, Pa., Jan. 11, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics...
Aprea Therapeutics Reports Third Quarter 2022 Financial Results and Provides Update on Business Operations
09 nov. 2022 16h15 HE
|
Aprea Therapeutics
BOSTON, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel synthetic lethality-based cancer...
Aprea Therapeutics Announces Poster Presentation at the 2022 Rivkin Center and American Association for Cancer (AACR) Virtual Ovarian Cancer Research Seminar Series
22 sept. 2022 18h00 HE
|
Aprea Therapeutics
BOSTON, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting...
Aprea Therapeutics to Participate in the 2022 H.C. Wainwright Global Investment Conference
08 sept. 2022 08h00 HE
|
Aprea Therapeutics
BOSTON, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting...
Aprea Therapeutics Reports Second Quarter 2022 Financial Results and Provides Update on Business Operations
11 août 2022 16h15 HE
|
Aprea Therapeutics
BOSTON, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel synthetic lethality-based cancer...